SUSMED,Inc.

As of December 31, 2024, SUSMED,Inc. carries a market capitalization of 10.18B, placing it among publicly traded companies globally. Its enterprise value stands at 5.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SUSMED,Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of December 31, 2024, SUSMED,Inc. has 16.81M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, SUSMED,Inc. maintains a current ratio of 13.64, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

Over the twelve months ended December 31, 2024, SUSMED,Inc. recorded 908,000.00 in income tax expense.

As of the close on October 22, 2026, SUSMED,Inc.'s stock has declined approximately 62.34% over the past 52 weeks. The 50-day moving average sits at 453.30, while the 200-day moving average is 770.65.

These figures are as of December 31, 2024. Total book value stands at 4.34B, with working capital of 4.29B providing operational flexibility.